<?xml version="1.0" encoding="UTF-8"?>
<p>The use of tocilizumab, a monoclonal antibody against IL-6, has recently been suggested as a treatment for COVID-19 patients at risk of cytokine storms.
 <xref rid="b90-dic-2020-4-15" ref-type="bibr">90</xref> Tocilizumab is an IL-6 inhibitor that may be effective in treating COVID-19.
 <xref rid="b91-dic-2020-4-15" ref-type="bibr">91</xref> The level of IL-6 was found to be correlated with the severity of COVID-19 and levels of C-reactive protein, lactate dehydrogenase, D-dimer, and T cells.
 <xref rid="b90-dic-2020-4-15" ref-type="bibr">90</xref> A retrospective study of 20 COVID-19 patients receiving tocilizumab found that 75% of them had decreased oxygen requirement.
 <xref rid="b92-dic-2020-4-15" ref-type="bibr">92</xref> According to The Diagnosis and Treatment Protocol from the China National Health Commission and State Administration of Traditional Chinese Medicine, tocilizumab can be used in patients with extensive pulmonary lesions and in patients with increased IL-6 levels.
 <xref rid="b66-dic-2020-4-15" ref-type="bibr">66</xref> Clinical trials on the efficacy of intravenous tocilizumab as a treatment for COVID-19 are ongoing.
 <xref rid="b93-dic-2020-4-15" ref-type="bibr">93</xref>,
 <xref rid="b94-dic-2020-4-15" ref-type="bibr">94</xref> However, serious adverse effects have been reported including gastrointestinal perforation, anaemia, hepatitis, and infusion reaction.
</p>
